Kanuma Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kanuma market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as increasing awareness of rare genetic disorders, a rising prevalence of pediatric LAL-D cases, the approval of enzyme replacement therapies such as Kanuma, improvements in healthcare infrastructure in emerging markets, and the expansion of insurance coverage for rare disease treatments.

Market growth during the forecast period can driven by factors including a growing demand for personalized medicine, an increased focus on the early diagnosis and treatment of rare diseases, the rising global prevalence of genetic disorders, government support for orphan drug development, and enhanced patient awareness campaigns. Key trends in the forecast period include advancements in diagnostic technologies for LAL-D, the introduction of innovative treatment delivery methods, breakthroughs in biotechnology and enzyme therapy development, partnerships between biotech companies and health authorities, and the development of combination therapies for rare diseases.

The rising prevalence of lysosomal acid lipase deficiency (LAL-D) is expected to drive the growth of the kanuma market in the coming years. LAL-D is a rare genetic disorder that causes lipid accumulation in organs, leading to liver dysfunction, cardiovascular issues, and metabolic disturbances. Improved diagnostic techniques and heightened awareness have led to better detection rates of this rare condition, contributing to its growing recognition. Kanuma, an enzyme replacement therapy, is used to treat LAL-D by replacing the deficient lysosomal acid lipase enzyme, helping reduce lipid buildup and prevent organ damage. According to a 2023 report by the National Institutes of Health, the disease's prevalence ranges from 1,40,000 to 1,300,000, depending on ethnicity and geographical location. This increasing prevalence of LAL-D is expected to fuel the demand for kanuma.

The rise in healthcare expenditure is key factor driving the growth of the kanuma market. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal healthcare, preventive services, and public health activities. This spending has been rising due to several factors, such as an aging population, chronic diseases, advancements in medical technology, and increased demand for healthcare services. The costs associated with enzyme replacement therapies such as Kanuma, including the drug itself, administration, and ongoing patient monitoring, are impacted by this rising healthcare expenditure. For instance, in May 2024, the Office for National Statistics in the UK reported that total healthcare expenditure increased by 5.6% from 2022 to 2023, with long-term health and social care expenditure also rising by 2.8%. These factors are likely to drive the kanuma market further.

A significant trend in the kanuma market is the emphasis on enzyme replacement therapy (ERT) to treat LAL-D and related conditions. Kanuma is a key ERT that addresses the lipid accumulation associated with LAL-D by providing the deficient enzyme. In November 2023, the National Health Service (NHS) in the UK approved sebelipase alfa (Kanuma) as the first treatment for Wolman disease, a rare and fatal genetic condition affecting infants and toddlers. This approval follows a commercial agreement between NHS England and a recommendation from the National Institute for Health and Care Excellence (NICE), further highlighting the role of enzyme replacement therapies in treating rare genetic disorders such as LAL-D.

The key company operating in the kanuma market is AstraZeneca PLC.

North America was the largest region in the kanuma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kanuma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kanuma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kanuma (sebelipase alfa) is a recombinant enzyme replacement therapy used to treat lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder. LAL-D causes the accumulation of lipids in tissues, leading to liver damage, cardiovascular problems, and other complications. Kanuma works by replacing the deficient LAL enzyme, helping to break down lipid deposits in the body.

The main indications for kanuma include the treatment of lysosomal acid lipase deficiency and associated conditions. The treatment of LAL-D primarily involves enzyme replacement therapy (ERT), such as Kanuma, to replace the missing lysosomal acid lipase enzyme. The product is available in injectable formulations and lyophilized powders for reconstitution. Patient demographics for Kanuma include pediatric, adult, and geriatric patients. The distribution channels include direct sales, wholesalers, retail pharmacies, and online pharmacies. Kanuma is used by various end users, including hospitals, specialty clinics, home healthcare providers, and research institutions.

The kanuma market research report is one of a series of new reports that provides kanuma market statistics, including kanuma industry global market size, regional shares, competitors with a kanuma market share, detailed kanuma market segments, market trends and opportunities, and any further data you may need to thrive in the kanuma industry. This kanuma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kanuma market consists of sales of single-dose vials, intravenous infusion solutions, and ready-to-use formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.